Implantica announces a Capital Markets Day in Stockholm to showcase its medtech pipeline, including RefluxStop®, aiming to attract investor interest in its $1 billion acid‑reflux market
Executive summary: Implantica AG announced it will host a Capital Markets Day in Stockholm on September 9, 2026 to showcase its medtech innovations, including the RefluxStop® device for acid reflux. The event aims to raise investor awareness and potentially unlock funding for a treatment area affecting roughly one billion people worldwide.
Who is involved: Implantica AG’s management and board, current and prospective shareholders, analysts, and the broader medtech investment community.
Likely next: On 2026-09-09 Implantica will present clinical data, financial outlook and may discuss partnership or financing opportunities at the Capital Markets Day.
Implantica AG said it will hold a Capital Markets Day in Stockholm on September 9, 2026 to present its medtech portfolio, highlighting the RefluxStop® device for acid reflux which addresses a patient base of roughly one billion. The event is intended to increase the company’s visibility among investors and analysts, potentially facilitating access to capital for further development and commercialisation of its therapies. By detailing clinical progress and financial outlook, Implantica seeks to reinforce confidence in its growth strategy within a large, underserved therapeutic area.
Timeline
- — Implantica to host Capital Markets Day in Stockholm on September 9 (PR Newswire)
- — Keymed Biosciences anuncia los resultados del primer semestre de 2026 y novedades empresariales (PR Newswire)
Analysis — what this means
Likely next events
- Implantica’s Capital Markets Day is scheduled for 2026-09-09 in Stockholm.
Sectors affected
- Medical devices – gastroenterology (acid reflux treatment)
- Implantable medical technology
Historical parallels
- Medtronic’s 2018 Investor Day highlighted its Micra transcatheter pacemaker.
- Boston Scientific’s 2020 Capital Markets Day showcased the Watchman left‑atrial closure device.
Sources
- Implantica to host Capital Markets Day in Stockholm on September 9 — PR Newswire
- Implantica to host Capital Markets Day in Stockholm on September 9 — PR Newswire
- Keymed Biosciences anuncia los resultados del primer semestre de 2026 y novedades empresariales — PR Newswire
Related cases
- Stockholm’s 17 identified startup and investor hotspots underscore the city’s rising role as a Nordic venture capital hub
- FDA approves Implantica's RefluxStop, clearing the way for US market entry of a new GERD treatment device
- FDA approval clears the way for Implantica’s RefluxStop to enter the U.S. GERD treatment market